We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Notice for palovarotene (Ipsen Pty Ltd)
Active ingredients
palovarotene
Sponsor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Capsule with hard shell
Indication
To reduce the formation of heterotopic ossification (HO) in patients with fibrodysplasia (myositis) ossificans progressiva (FOP)
Therapeutic area
Musculoskeletal